[ad_1]
Concerns about becoming confidence issues in the pharmaceutical industry as a whole …
Commit to doing everything possible to avoid repetition, such as the general quality control inspection of member companies in the wake of this incident.
“I can’t help but be surprised that the Binex case is an unacceptable crime.”
The Korea Pharmaceutical Bio Association announced this position in connection with Binex’s voluntary change in the pharmaceutical manufacturing process.
The Ministry of Food and Pharmaceutical Safety recently confirmed that Binex has taken steps to stop manufacturing and selling 32 items consigned to production from 24 companies after confirming the voluntary change in the quantity and manufacturing method of the main raw materials for medicines.
In this regard, the association said in a statement on the 11th, “The facts will be revealed through additional investigations by the Ministry of Food and Pharmaceutical Safety, but it is a shock because it is a crime that cannot be tolerated.” that have a profound impact on people’s health and lives “This should never happen in pharmaceutical companies that produce products.”
The association said it would take the case very seriously and follow up. The association said: “In addition to further investigations by the Ministry of Food and Drug Safety, we will fully understand the facts as soon as possible and take decisive action, such as referral to the ethics committee.” We will take quick action, such as checking the overall situation. “
In addition, to avoid the repetition of similar events, “consignment and co-promotion to avoid confusion such as unrestricted consignment production of generic drugs. We will do our best to achieve a reasonable improvement in the development system.”
Taking into account all the problems stemming from the generic drug outbreak in 2017, the association proposed to the government to limit the number of subcontracted and coexistence items to four, including the original manufacturer. We continue to strive with our member companies. “
Regarding this situation, the Bio Pharmaceutical Association said: “I hope that the deviations and exceptional offenses of specific companies do not become a problem of confidence for the entire industry.” I will use the situation as an opportunity for my intense complacency. “
Copyright holder © Prohibition of unauthorized reproduction and redistribution
